Clinical trials: HBP
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Hypertension
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension.
- Trial name
- NCT03934307
- Testing
- ALN-AGT01, Irbesartan
- Where
- 3 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- Alnylam Pharmaceuticals
Pregnancy Complications, Pregnancy Outcome
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
The purpose of this study is to determine if inadvertent receipt of the BioThrax vaccine during pregnancy is independently associated with adverse maternal, pregnancy, or infant health outcomes.
- Conditions
- Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
- Trial name
- NCT01653392
- Testing
- Observational Intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Glaucoma
Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome
The purpose of this study is to assess and compare the mechanical angle opening in patients with angle closure due to a plateau iris configuration (elevated iris) using phacoemulsification combined with endoscopic cycloplasty…
- Trial name
- NCT02049333
- Testing
- Phacoemulsification, Endoscopic Cycloplasty (ECPL)
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Credit Valley EyeCare
Glaucoma
Minimally Invasive Micro Sclerostomy: Performance and Safety Evaluation Study
Eligible Glaucoma patients will undergo pre-surgery examination including: medicines list, blood tests and ECG. On surgery day: intraocular pressure (IOP) will be measured.
- Trial name
- NCT04503590
- Testing
- Minimally Invasive Micro Sclerostomy (MIMS)
- Where
- Armenia
- Volunteers
- 120 people
- Sponsor
- Sanoculis Ltd
Essential Hypertension
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week…
- Trial name
- NCT06500689
- Testing
- Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil
- Where
- 40 sites in China
- Volunteers
- 366 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Ocular Hypertension, Open Angle Glaucoma
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04360174
- Testing
- OTX-TIC
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ocular Therapeutix, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02325518
- Testing
- Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy
- Where
- Japan
- Volunteers
- 218 people
- Sponsor
- Alcon, a Novartis Company
Open-angle Glaucoma (OAG)
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
- Trial name
- CREST-XT (NCT07480343)
- Testing
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Iantrek, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs…
- Trial name
- NCT02742649
- Testing
- Fixed Combination, Bimatoprost, Timolol
- Where
- Panama
- Volunteers
- 55 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Open-Angle
Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of a novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma…
- Trial name
- SAFARI (NCT03736655)
- Testing
- Interposition supraciliary implant
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Ciliatech
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Hypertension, Type 2 Diabetes
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit.
- Trial name
- NCT00803660
- Where
- 19 sites in Vietnam
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00350168
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- Novartis
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Pulmonary Hypertension
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00760916
- Testing
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg
- Where
- 31 sites in United States, Australia and 1 more
- Sponsor
- United Therapeutics
Hypertension, Congestive Heart Failure
Bioavailability Study of BIA 5-453
The purpose of this study was to compare the bioavailability and tolerability of BIA 5-453 under fasted and fed conditions.
- Trial name
- NCT03090568
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
The primary objectives of this trial is to demonstrate that the fixed-dose combination of telmisartan 80mg plus amlodipine 5mg (T80/A5) is superior to amlodipine 5mg (A5) in reducing seated trough diastolic blood pressure (DBP)…
- Trial name
- NCT01103960
- Testing
- Telmisartan80mg+Amlodipine5mg, amlodipine 5mg, Telmisartan80mg+Amlodipine 5mg
- Where
- 16 sites in China, Malaysia and 1 more
- Volunteers
- 324 people
- Sponsor
- Boehringer Ingelheim
Glaucoma, Retinal Disease
OCT Agreement and Crossed Precision Study
The purpose of this study is to asses the agreement of the RS-3000 Lite and RS-3000 Advance to the RS-3000, assess the crossed precision of each study device and to assess the transference of a reference database from the RS-3000…
- Conditions
- Glaucoma, Retinal Disease, Corneal Disease
- Trial name
- NCT02050880
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Nidek Co. LTD.
Open-Angle Glaucoma, Ocular Hypertension
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma…
- Trial name
- NCT00918346
- Testing
- Tafluprost 0.0015%
- Where
- 3 sites in Finland, Germany
- Volunteers
- 43 people
- Sponsor
- Santen Oy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.